Q-omics provides the consensus-scored LMNA profile across patient tissues and cancer cell-line models. LMNA expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LMNA is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, LMNA protein abundance shows 34,455 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, KIRC, and PDAC as cancer lineages where LMNA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LMNA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LMNA survival associations across molecular data types. LMNA RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LMNA RNA expression–survival associations across cancer types. High LMNA expression shows unfavorable associations in ACC, BLCA, MESO, LGG, READ and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LMNA RNA expression.
This table summarizes LMNA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LMNA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LMNA shows lower tumor expression in KICH and BLCA and higher tumor expression in KIRC, HNSC, LIHC and THCA. The KIRC box plot shows higher LMNA RNA expression in tumor versus normal tissue (log2 FC = +0.750, t-test p < 0.001).
This table shows molecular features associated with LMNA in patient tissues and cancer cell lines. In patient samples, LMNA shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, LMNA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
